Latest research on Candesartan

Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Candesartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.

Latest findings

However, recent studies in hypertensive patients have demonstrated that treatment with the novel angiotensin receptor blocker (ARB) Azilsartan persistently lowers blood pressure over a 24-h period compared with other ARBs, and improves nocturnal hypertension more effectively than Candesartan [22–24], suggesting that Azilsartan has potential to restore the circadian rhythm of blood pressure. [source, 2016]
Two weeks later, each of the groups was administered Azilsartan, Candesartan cilexetil, or vehicle. [source, 2016]
Azilsartan and Candesartan cilexetil were resuspended in 0.5% methylcellulose (Wako Pure Chemical Industries, Osaka, Japan) at 1.0 mg/kg and 0.3 mg/kg, respectively, and administered by gastric gavage once daily. [source, 2016]
Doses of the two anti-hypertensive drugs were determined according to the highest doses used in humans (40 mg/day for Azilsartan and 12 mg/day for Candesartan). [source, 2016]
Azilsartan, Candesartan cilexetil (for oral administration) and Candesartan (for in vitro studies) were provided by Takeda Pharmaceutical Company Ltd. [source, 2016]
Once confluent, the OK cells were treated with Azilsartan (1.0 × 10−6 mol/l), Candesartan (3.0 × 10−7 mol/l), or vehicle for 24 h, and simultaneously with angiotensin II (1.0 × 10−11 mol/l). [source, 2016]
To measure the ubiquitination of total cellular NHE3, OK cells (60–80% confluent) were transiently transfected with a hemagglutinin (HA)-tagged ubiquitin (HA-Ub) expression vector, then treated with Azilsartan (1.0 × 10−6 mol/l), Candesartan (3.0 × 10−7 mol/l), or vehicle for 24 h, as described above. [source, 2016]
To investigate the effect of Azilsartan and Candesartan on salt-sensitive hypertension, 5/6 Nx mice were fed a high-salt diet (8% NaCl) and a medium-salt diet (4% NaCl) as a model of salt-sensitive hypertension. [source, 2016]
Although 5/6 Nx mice on a high-salt diet exhibited significantly elevated blood pressure compared with those on a normal-salt diet (117.9 ± 2.5 vs. 101.2 ± 1.9 mmHg, P < 0.05), treatment with Azilsartan or Candesartan significantly reduced the blood pressure of mice fed a high-salt diet (Azilsartan: 103.1 ± 1.0; Candesartan: 111.7 ± 2.7; vehicle: 125.5 ± 2.5 mmHg; P < 0.05 Azilsartan or Candesartan vs. vehicle) (Fig 1A). [source, 2016]
Notably, Azilsartan was more effective at reducing blood pressure than Candesartan (P < 0.05). [source, 2016]